RXDX News and Press, Prometheus Biosciences Inc. From 02/28/23

Prometheus Biosciences press release ( NASDAQ: RXDX ): Q4 GAAP EPS of -$0.90 beats by $0.01 . Revenue of $0.65M (-37.5% Y/Y) beats by $0.18M . For further details see: Prometheus Biosciences GAAP EPS of -$0.90 beats by $0.01, revenue of $0.65M beats by $0.18M

– Reported strong efficacy and favorable safety results for PRA023 in ARTEMIS-UC and APOLLO-CD Phase 2 Studies – – Prometheus intends to advance PRA023 into Phase 3 studies for UC and CD in 2023 – – Initiated a third Phase 2 of PRA023 into ...

Summary Prometheus Biosciences has strong growth potential. Minimal competition ensures demand for its products. RXDX stock is trading at an attractive valuation. For further details see: Prometheus Biosciences: Strong Growth

- Digital Oral Presentation on APOLLO-CD Phase 2a primary and secondary results to be presented on March 3 r d - - Oral Presentation on ARTEMIS-UC Phase 2 primary and secondary endpoint data from Cohort 1 to be presented on March 4 th - SAN DIEGO, F...

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases,...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

The following slide deck was published by Prometheus Biosciences, Inc. in conjunction with this event. For further details see: Prometheus Biosciences (RXDX) Presents At 41st Annual Healthcare Conference - Slideshow

Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatm...

Shares of Prometheus Biosciences (NASDAQ: RXDX) nearly tripled on Wednesday, Dec. 7, 2022. Investors were cheering for some surprisingly good news regarding the clinical-stage biotechnology company's lead candidate. Prometheus Biosciences' stock price rocketed higher thanks to signs t...